WPWeihua Pan

Weihua Pan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Weihua Pan has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Deconstructing Anterior Segment Crowding: Preoperative Anatomical Predictors of Malignant Glaucoma After Primary Angle-Closure Glaucoma Surgery

    by Yan Zhang, Junbo Liu, Chunlan Gao, Xuming Ding, Weihua Pan, Xuanchu Duan

    Understanding anterior segment crowding is essential for identifying preoperative risk factors for malignant glaucoma (MG) following phacoemulsification, intraocular lens implantation, and goniosynechialysis (PEI‒GSL) in primary angle-closure glaucoma (PACG). This retrospective case-control study compared 24 PACG patients who developed postoperative MG (MG group) to 24 randomly selected controls (control group). Preoperative ultrasound biomicroscopy (UBM) metrics included anterior chamber depth (ACD), lens vault (LV), ciliary process distance (CCD), ciliary body thickness, anterior ciliary body placement, trabecular‒ciliary process angle (TCPA), and simulated cilio-lenticular distance (sCLD). To eliminate observer bias, all exported raw UBM images were completely anonymized, stripped of all identifiable metadata, randomized, and assigned unique computer-generated hashes before undergoing single-blinded evaluation. The MG group exhibited significantly shorter sCLD, greater LV, shallower ACD, and narrower TCPA preoperatively, with standardized mean differences exceeding 0.8. After False Discovery Rate correction, these differences remained significant (adjusted P < 0.05). Crucially, multivariable logistic regression adjusting for axial length (AL) demonstrated that a shortened sCLD (P < 0.001), an increased LV (P < 0.001), and a narrowed TCPA (adjusted P = 0.0099) maintained highly robust independent associations with MG development. The MG group showed a trend of weakened parameter coordination, particularly between AL and ACD (r = 0.334 vs. 0.718). Exploratory principal component analysis identified an architectural "anterior segment crowding" axis (explaining 62.2% of the variance), with the MG group clustering negatively. An exploratory, unweighted composite ciliary block score showed a large separation effect size (Cohen's d = 1.995, P < 0.001). In conclusion, preoperative shortened sCLD, increased LV, and narrowed TCPA constitute an anatomical risk cluster independently associated with postoperative MG. While anterior segment crowding characterizes this cohort, these multivariate models function strictly as exploratory, sample-specific constructs and explicitly lack external clinical validation.

  • Open Access

    Long-term outcomes of phacoemulsification and intraocular lens implantation combined with goniosynechialysis for primary angle-closure glaucoma with 360° peripheral anterior synechiae

    by Junhua Li, Yuchen Gu, Hengli Lian, Na Li, Liqing Wei, Wanting Wu, Tingting Li, Weihua Pan

    Phacoemulsification combined with intraocular lens implantation and goniosynechialysis (PEI + GSL) represents a mainstream ​surgical technique​for the treatment of primary angle-closure glaucoma (PACG). As the disease progresses, when the extent of peripheral anterior synechiae (PAS) gradually expands to 360°, whether PEI + GSL remains effective remains uncertain. This study aimed to investigate the long-term clinical efficacy​of PEI + GSL in treating PACG patients with 360° PAS. A case‒control study was conducted on PACG patients with 360° PAS (360° PAS group) and those with PASs ranging from 90° to 180° (90°≤ PAS ≤ 180° group). Patients underwent PEI + GSL and were followed up for 1–3 years. The data collected included intraocular pressure (IOP), glaucoma medications, visual acuity, PAS extent, complications, and other relevant parameters. Kaplan‒Meier curves were used to analyse the cumulative surgical success rates in both groups. The 360° PAS group included 31 eyes (31 patients), and the 90°≤ PAS ≤ 180° group included 32 eyes (32 patients). At the final follow-up (36 months), the IOP was 14.8 ± 3.9 mmHg in the 360°PAS group and 15.5 ± 2.9 mmHg in the 90°≤ PAS ≤ 180° group (P = 0.507). The degree of IOP reduction was 47.9% in the 360°PAS group and 33.0% in the 90°≤ PAS ≤ 180° group (P = 0.272). The mean number of glaucoma medications decreased by 2.5 in the 360°PAS group and 1.1 in the 90°≤ PAS ≤ 180° group (P < 0.001). The complete plus qualified success rates at 3 years were 90.3% and 93.8%, respectively, with no significant difference (P = 0.970). PEI + GSL in PACG patients with 360° PAS resulted in a 47.9% reduction in IOP, a mean reduction of 2.5 glaucoma medications, and a high overall surgical success rate (90.3%), comparable to the 90°≤ PAS ≤ 180° group (93.8%). ChiCTR2400086966 The study protocol was approved in the Chinese Clinical Trial Registry at 2024-07-16.


  • Open Access

    Comparison of Ahmed Glaucoma Valve Implantation Alone Versus Combined with Phacoemulsification in Chinese Primary Open-Angle Glaucoma

    by Lin Fu, Xinyi Liu, Yijing Ping, Xiaoyu Zhuang, Shumeng Yao, Shuhan Yu, Hexiang Wang, Shenglu Yao, Weihua Pan

    Introduction: To compare the surgical outcomes of Ahmed glaucoma valve (AGV) implantation and combined AGVwith phacoemulsification (Phaco-AGV) in Chinese patients with primary open-angle glaucoma (POAG). Methods: A total of 43 eyes followed up for 2 years were enrolled. The primary outcome was the success rate. The success rate was defined as an IOP of 5– 21 mmHg (success rate 1) or 5– 18 mmHg (success rate 2), and an IOP reduction of more than 20% with (qualified) or without (complete) glaucoma medications. The secondary outcomes included IOP, glaucoma medications, and complications. Results: Eighteen eyes underwent AGV and 25 eyes underwent phaco-AGV. There were no differences in the preoperative IOP (25.7 ± 10.7 mmHg vs 26.3 ± 6.2 mmHg, P< 0.05) and medications (2.1 ± 1.4 vs 1.6 ± 0.8, P< 0.05) between the two groups. The complete success rate 1 in the Phaco-AGV group was higher than that in the AGV group at the 2-year (60.0% vs 22.2%, P< 0.05) follow-up. The qualified and complete success rates 2 in the Phaco-AGV group were both higher than those in the AGV group at the 2-year follow-up (all P < 0.05). Patients in the Phaco-AGV group showed significantly lower postoperative IOP at 3 months (P< 0.05), used fewer glaucoma medications at month-3, month-6 and year-2 visits, experienced less encapsulated blebs than those in the AGV group (P< 0.05). Conclusion: The surgical outcomes of phaco-AGV showed higher success rates and fewer complications than those of AGV in this 2-year study.


  • Open Access

    Tacrolimus eye drops treatment for recurrent exposure of the Ahmed glaucoma valve tube

    by Li-Li Chen, Yu Chen, Lin Fu, Li-Qing Wei, Wei-Hua Pan

    To investigate the effectiveness and safety of 0.1% tacrolimus eye drops in treating recurrent exposure after initial repair of Ahmed glaucoma valve tubes. After reviewing all patients who underwent AGV implantation at a single center from January 2016 to March 2022, 11 patients (11 eyes) were enrolled in this retrospective study and divided into two treatment groups: a study group and a control group. All GDDs were initially implanted with AGV and were followed up for at least 1 year. All patients experienced drainage tube exposure after the first operation and subsequently underwent secondary surgical treatment. When postoperative observations revealed that the conjunctiva began to dissolve at the edge of the drainage tube, patients in the study group (n = 5) received topical 0.1% tacrolimus eye drops twice daily, while patients in the control group (n = 6) received tobramycin 0.3%/dexamethasone 0.1% eye drops four times daily. The mean treatment duration for both groups was 1.64 ± 0.67 months (range: 1–3 months). The subjective eye symptoms and objective eye signs were evaluated by the same ophthalmologist. In the study group, conjunctival dissolution recurred in 5 patients (5 eyes) at an average of 14 ± 11 days (range: 7–33 days) after the initial repair. Four eyes underwent allogeneic scleral patch grafting, whereas one eye was repaired with an autologous scleral tunnel. In the control group, conjunctival dissolution recurred in 6 patients (6 eyes) at an average of 15 ± 9 days (range: 7–29 days) after the initial repair. Four eyes were treated with allogeneic scleral patch transplantation, while two eyes were repaired using autologous conjunctival transplants. The primary clinical manifestations in both groups were bulbar conjunctival perforations and erosion. Notably, all patients in the study group achieved complete healing within an average of 17 ± 2.0 days (range: 15–20 days) after treatment with 0.1% tacrolimus eye drops, with no adverse reactions observed during follow-up evaluations. In contrast, in the control group, conjunctival erosion persisted despite treatment with tobramycin 0.3%/dexamethasone 0.1% eye drops for an average duration of 1.83 ± 0.75 months (range: 1–3 months), leading to prolonged drainage tube exposure. Treatment with 0.1% tacrolimus eye drops demonstrated satisfactory results in managing recurrent exposure following allogeneic scleral patch graft coverage and autologous scleral tunnel repair, suggesting its potential as an effective alternative to conventional treatments.

  • Open Access

    Use of double short tandem scleral tunnels for repairing eroded ahmed glaucoma valve tubes

    by Jun Yu, Xiangjun Dai, Xiaohua Chen, Xiaoming Gao, Weihua Pan

    To evaluate the effectiveness and safety of a method for repairing an eroded Ahmed glaucoma valve (AGV) tube using two short scleral tunnels made in tandem with a 22G needle instead of covering the eroded tube with another scleral graft. From May 12, 2015, to July 27, 2019, we retrospectively reviewed eight patients at Ningbo Aier Eye Hospital who developed AGV tube erosion secondary to necrosis of their overlying conjunctiva and scleral grafts. This defect was repaired in all the patients using the double short tandem scleral tunnel technique, which involved the creation of double short tandem scleral tunnels made by a 22G needle. Two parallel-to-limbus scleral incisions were made 3 mm and 6 mm from the limbus first, then a curved 22G needle was inserted between the two scleral cuts to make one scleral tunnel, the other scleral tunnel was completed during the first surgery, inserted the tube into the two tunnels. The mean length of time between the AGV placement and the first erosion was 12.25 ± 6.36 months (3–24 months). The mean age of the patients was 65.50 ± 11.70 years (49–78 years). The surgical outcome was assessed in terms of the tectonic integrity of the conjunctiva over the follow-up period (12 months). There was no AGV tube erosion, scleral thinning, or ocular infection after a mean of 41.25 ± 26.54 months of follow-up in all eight patients. AGV tube erosion following shunt surgery can be successfully managed using the improved double short tandem scleral tunnel technique.

  • Effective treatment for secondary angle-closure glaucoma caused by traumatic lens subluxation: phacoemulsification with capsular-tension-ring implantation combined with ophthalmic endoscope-controlled goniosynechialysis

    by Qi Dai, Xin-Yi Liu, Wei-Hua Pan, Lin Fu

    AIM: To investigate the safety and efficacy of phacoemulsification with capsular-tension-ring implantation and posterior chamber intraocular lens implantation combined with ophthalmic endoscope-controlled goniosynechialysis (Phaco-CTR-IOL-OE-GSL) for treating secondary angle-closure glaucoma induced by traumatic lens subluxation. METHODS: A retrospective and descriptive study was performed on patients with lens subluxation, angle closure, goniosynechia, and evaluated intraocular pressure (IOP) that cannot be controlled with medication, who underwent Phaco-CTR-IOL-OE-GSL. The postoperative best-corrected visual acuity (BCVA), IOP, range of goniosynechia and complications were retrospectively observed. RESULTS: Nine patients with secondary angle-closure glaucoma induced by traumatic lens subluxation were included. The follow-up period was 51.1 +/- 8.6mo. The preoperative range of zonule rupture was 158.2 degrees +/- 33.0 degrees, and the range of goniosynechia was 220.0 degrees +/- 92.5 degrees. The baseline BCVA was 0.9 +/- 1.0 logMAR, IOP was 30.7 +/- 17.3 mm Hg, and number of anti-glaucoma medication was 3.2 +/- 1.1. Mild intraoperative hyphaemia with 8 eyes (88.8%) in the anterior chamber, and was absorbed two days postoperatively. One eye (11.1%) had postoperative ciliary body detachment and was recovered after five days of topical drug treatment. BCVA was 0.2 +/- 0.2 logMAR at 3mo postoperatively. The average IOP at the last follow-up was 16.7 +/- 2.0 mm Hg, and no anti-glaucoma medications were used. The average range of recurrent goniosynechia was 54.9 degrees +/- 33 degrees at the final postoperative gonioscopic examination. CONCLUSION: Phaco-CTR-IOL-OE-GSL is safe and effective in the treatment of secondary angle-closure glaucoma induced by traumatic lens subluxation. The use of an endoscope provides a more direct and clear examination for GSL, and 360 degrees dissection is easily achieved.


  • Open Access

    The Progression of Peripheral Anterior Synechia after Combined Phacoemulsification with Goniosynechialysis Under an Ophthalmic Endoscope: A Three-Year Study

    by Xinyi Liu, Yau Kei Chan, Lin Fu, Yunhe Song, Junhua Li, Li Nie, Xiulan Zhang, Weihua Pan

    Aim To investigate the long-term changes of peripheral anterior synechia (PAS) after phacoemulsification with goniosynechialysis under an ophthalmic endoscope (Phaco-OE-GSL) in primary angle-closure glaucoma (PACG) assisted with viscoelastics alone or viscoelastics combined with iris repositor (viscoelastics-repositor). Method A retrospective study was conducted. Thirty-nine eyes of 31 PACG patients were included. The follow-up period was 36 months. The main outcomes of the study included the changes of PAS, intraocular pressure (IOP), and the success rate.Results Phaco-OE-GSL was performed assisted with viscoelastics-alone on 20 eyes, and viscoelastics-repositor on 19 eyes. The total recurrence rates of PAS were 62.5% in viscoelastics-alone group and 87.5% in viscoelastics-repositor group. In particular, the recurrence rate of PAS at the same location at which were separated intraoperatively were 37.3% and 75.0% respectively (P=0.033). The recurrence of PAS was observed in 2 eyes in viscoelastics-alone group and 12 eyes in viscoelastics-repositor group within 1-month follow-up (P0.05). The extent of postoperative PAS at final follow-up was positively correlated with the range of PAS preoperatively (P=0.036, r=0.356). The complete success rates were 85.0% and 89.5% of viscoelastics-alone group and viscoelastics-repositor group at 36-month follow-up respectively. Both the preoperative and postoperative distribution of PAS are mainly concentrated on the upper (84.6% and 95.8%) and nasal side (74.4% and 62.5%), followed by the inferior side, and the least on the temporal side. Conclusion In summary, although the recurrence rate of PAS was high in early postoperative period, the progression of PAS was rapidly resolved after 6 months postoperatively, and Phaco-OE-GSL is an effective treatment for the long-term control of IOP of PACG patients especially with large range of PAS (> 180°). Both preoperative and postoperative PAS are mainly concentrated on the upper and nasal side. Besides, our results suggested that mechanical separation may be easier to promote the progression of postoperative PAS than viscoelastics-alone separation.

  • Cataract Surgery (Phacoemulsification with Intraocular Lens Implantation) Combined with Endoscopic Goniosynechialysis for Advanced Primary Angle-Closure Glaucoma

    by Zhenbin Qian, Jinhai Huang, Benhao Song, Liqing Wei, Lin Fu, Michael W. Austin, George L. Spaeth, Weihua Pan, Colm McAlinden


  • Open Access

    Long term outcomes of cataract surgery in severe and end stage primary angle closure glaucoma with controlled IOP: a retrospective study

    by Lin Fu, Yau Kei Chan, Junhua Li, Li Nie, Na Li, Weihua Pan

    Background: To investigate the long term surgical outcomes of cataract surgery in severe and end stage glaucoma patients with preoperative intraocular pressure less than 21 mmHg, and to detect the associated factors. Methods: A retrospective study of primary angle closure glaucoma patients was conducted on who underwent cataract surgery or combined with goniosynechialysis from March 2015 to April 2018. Main outcome measures were visual acuity, intraocular pressure, number of glaucoma medications and complications. Results: Sixteen patients (19 eyes) were included. The mean age was 64.89 ± 11.68 years and the mean followed up duration was 21.89 ± 7.85 months. The final visual acuity was significantly improved from 0.69 ± 0.55 to 0.46 ± 0.52 logMAR, within 12 (63.2%) eyes improved, 4 (21.1%) eyes kept unchanged, and 3 (15.8%) eyes reduced. Linear regression analysis indicated that higher mean deviation, higher visual field index and lower glaucoma stage associated with better final visual acuity (r = − 0.511, r = − 0.493, r = 0.537 respectively). Moreover, the final number of medications were reduced from 1.26 ± 0.99 to 0.26 ± 0.56 (p < 0.01). The mean intraocular pressure was not significantly reduced with the final IOP of 14.48 ± 3.74 mmHg (p = 0.97). While the eyes with intraocular pressure above 15 mmHg was decreased to 6 (31.6%) eyes compared to 10 (52.6%) eyes at baseline. Moreover, the number of eyes free of medications was increased from 4 (21.1%) preoperatively to 15 (78.9%) eyes postoperatively. Conclusions: Final visual acuity was significantly improved in the severe and end stage primary angle closure glaucoma patients and the number of eyes came off medications increased by 57.8% after cataract surgery. Preoperatively, the glaucoma stage, mean deviation and visual field index are important parameters to predict the final visual acuity after cataract surgery.


  • Open Access

    Evaluation of Two Different Anterior Vitrectomies for Fluid Misdirection Syndrome Secondary to Cataract Surgery Combined with Goniosynechialysis

    by Zhenbin Qian, Yau Kei Chan, Liqing Wei, Bin Zheng, Li Nie, Weihua Pan

    Purpose. To evaluate two different approaches of anterior vitrectomy combined with hyaloidotomy, zonulectomy, and iridectomy (VHZI) for fluid misdirection syndrome (FMS) secondary to phacoemulsification with intraocular lens implantation combined with goniosynechialysis (phaco-IOL-GSL). Methods. Nine patients with FMS who developed after a phaco-IOL-GSL procedure, were retrospectively studied from May 2015 to February 2018. They were treated with VHZI, in which 5 cases underwent local anterior vitrectomy via anterior chamber approach, and the others underwent comprehensive vitrectomy via pars plana approach. Main outcome measures were pre- and postoperative intraocular pressure (IOP), number of antiglaucoma medications, and relapse rate. Results. Incidence of FMS secondary to phaco-IOL-GSL was 1.4% (9 in 652 eyes), which was promptly resolved in all affected cases. VHZI via anterior chamber approach resulted in a significant decrease in the mean IOP from 40.2 ± 9.7 mm Hg at presentation to 15.2 ± 4.8 mm Hg postoperatively (P=0.01). The median number of antiglaucoma medications reduced from 3 to 2 (P=0.066). Meanwhile, VHZI via pars plana approach also resulted in the reduction of the mean IOP values from 26.0 ± 5.7 mm Hg at presentation to 15.2 ± 3.3 mm Hg postoperatively (P=0.092). The median number of antiglaucoma medications also reduced from 3.5 to 1.5 (P=0.059). Relapse rate of the treatment through pars plana approach (0%, 0/4) was much lower than that through anterior chamber approach (40%, 2/5), although the difference was not statistically significant (P=0.444). Conclusions. FMS is a rare but severe complication secondary to phaco-IOL-GSL. Compared to VHZI with local anterior vitrectomy via anterior chamber approach, VHZI with comprehensive anterior vitrectomy via pars plana approach might be a more effective procedure to treat FMS. The study has been registered in Contact ClinicalTrials.gov PRS Identifier: NCT04172857.